{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:21Z","timestamp":1793413881426,"version":"4.5.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s43441-026-01033-8","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:12:03Z","timestamp":1786713123000},"page":"1648-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision Lipid Management in the Era of Biotechnology and Artificial Intelligence: From Gene Editing to Smart Drug Delivery"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3066-1921","authenticated-orcid":false,"given":"Esra","family":"Palabiyik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"12","key":"1033_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101342","volume":"47","author":"T Abdul-Rahman","year":"2022","unstructured":"Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, et al. Lipid lowering therapy: an era beyond statins. Curr Probl Cardiol. 2022;47(12):101342. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101342.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"1033_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051251","volume":"13","author":"F Agnello","year":"2024","unstructured":"Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management. J Clin Med. 2024;13(5):1251. https:\/\/doi.org\/10.3390\/jcm13051251.","journal-title":"J Clin Med"},{"issue":"1\u20133","key":"1033_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14779072.2023.2288169","volume":"22","author":"F Agnello","year":"2024","unstructured":"Agnello F, Mauro MS, Rochira C, Landolina D, Finocchiaro S, Greco A, et al. PCSK9 inhibitors: current status and emerging frontiers in lipid control. Expert Rev Cardiovasc Therapy. 2024;22(1\u20133):41\u201358. https:\/\/doi.org\/10.1080\/14779072.2023.2288169.","journal-title":"Expert Rev Cardiovasc Therapy"},{"issue":"5","key":"1033_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","volume":"107","author":"CA Aguilar-Salinas","year":"2022","unstructured":"Aguilar-Salinas CA, G\u00f3mez-D\u00edaz RA, Corral P. New therapies for primary hyperlipidemia. J Clin Endocrinol Metab. 2022;107(5):1216\u201324. https:\/\/doi.org\/10.1210\/clinem\/dgab876.","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/eurheartj\/ehy404","volume":"40","author":"SJ Al\u2019Aref","year":"2019","unstructured":"Al\u2019Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. Eur Heart J. 2019;40(24):1975\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehy404.","journal-title":"Eur Heart J"},{"key":"1033_CR6","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S338424","author":"MS Albosta","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023. https:\/\/doi.org\/10.2147\/VHRM.S338424.","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"1033_CR7","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/microorganisms12112341","volume":"12","author":"L Alexandrescu","year":"2024","unstructured":"Alexandrescu L, Suceveanu AP, Stanigut AM, Tofolean DE, Axelerad AD, Iordache IE, et al. Intestinal insights: the gut microbiome\u2019s role in atherosclerotic disease: a narrative review. Microorganisms. 2024;12(11):2341. https:\/\/doi.org\/10.3390\/microorganisms12112341.","journal-title":"Microorganisms"},{"key":"1033_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1181720","volume":"10","author":"M Allevi","year":"2023","unstructured":"Allevi M, Sarnari S, Giulietti F, Spannella F, Di Pentima C, Sarzani R. Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report. Front Cardiovasc Med. 2023;10:1181720. https:\/\/doi.org\/10.3389\/fcvm.2023.1181720.","journal-title":"Front Cardiovasc Med"},{"key":"1033_CR9","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X16999201210200342","author":"A Alloubani","year":"2021","unstructured":"Alloubani A, Nimer R, Samara R. Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review. Curr Cardiol Rev. 2021. https:\/\/doi.org\/10.2174\/1573403X16999201210200342.","journal-title":"Curr Cardiol Rev"},{"issue":"8","key":"1033_CR10","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/pharmaceutics16081037","volume":"16","author":"I Alradwan","year":"2024","unstructured":"Alradwan I, Al Fayez N, Alomary MN, Alshehri AA, Aodah AH, Almughem FA, et al. Emerging trends and innovations in the treatment and diagnosis of atherosclerosis and cardiovascular disease: a comprehensive review towards healthier aging. Pharmaceutics. 2024;16(8):1037. https:\/\/doi.org\/10.3390\/pharmaceutics16081037.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1033_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcph.2337","volume":"64","author":"G An","year":"2024","unstructured":"An G. Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs. J Clin Pharmacol. 2024;64(1):45\u201357. https:\/\/doi.org\/10.1002\/jcph.2337.","journal-title":"J Clin Pharmacol"},{"key":"1033_CR12","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S429411","author":"M Asmamaw Mengstie","year":"2024","unstructured":"Asmamaw Mengstie M, Teshome Azezew M, Asmamaw Dejenie T, Teshome AA, Tadele Admasu F, Behaile Teklemariam A, et al. Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing. Biol Targets Therapy. 2024. https:\/\/doi.org\/10.2147\/BTT.S429411.","journal-title":"Biol Targets Therapy"},{"key":"1033_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132315","volume":"412","author":"M Athar","year":"2024","unstructured":"Athar M. Potentials of artificial intelligence in familial hypercholesterolemia: advances in screening, diagnosis, and risk stratification for early intervention and treatment. Int J Cardiol. 2024;412:132315. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132315.","journal-title":"Int J Cardiol"},{"issue":"6","key":"1033_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","volume":"76","author":"JS Bajaj","year":"2022","unstructured":"Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol. 2022;76(6):1379\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.003.","journal-title":"J Hepatol"},{"issue":"1","key":"1033_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2022.1988568","volume":"21","author":"Y Banerjee","year":"2022","unstructured":"Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A, et al. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022;21(1):9\u201320. https:\/\/doi.org\/10.1080\/14740338.2022.1988568.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1033_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5543\/ucard.2019.09719","volume":"3","author":"\u00d6 Ba\u015faran","year":"2020","unstructured":"Ba\u015faran \u00d6. Statin intolerans. Updates Cardiol. 2020;3(1):20\u20134. https:\/\/doi.org\/10.5543\/ucard.2019.09719.","journal-title":"Updates Cardiol"},{"issue":"1","key":"1033_CR17","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1038\/s41598-021-86384-y","volume":"11","author":"AM Bea","year":"2021","unstructured":"Bea AM, Franco-Marin E, Marco-Bened\u00ed V, Jarauta E, Gracia-Rubio I, Cenarro A, et al. ANGPTL3 gene variants in subjects with familial combined hyperlipidemia. Sci Rep. 2021;11(1):7002. https:\/\/doi.org\/10.1038\/s41598-021-86384-y.","journal-title":"Sci Rep"},{"issue":"3","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10557-021-07293-w","volume":"37","author":"S Bellosta","year":"2023","unstructured":"Bellosta S, Rossi C, Alieva AS, Catapano AL, Corsini A, Baragetti A. Cholesterol lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. A pre-clinical perspective review. Cardiovasc Drugs Ther. 2023;37(3):585\u201398. https:\/\/doi.org\/10.1007\/s10557-021-07293-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/lipd.12290","volume":"56","author":"G Benincasa","year":"2021","unstructured":"Benincasa G, de Candia P, Costa D, Faenza M, Mansueto G, Ambrosio G, et al. Network medicine approach in prevention and personalized treatment of dyslipidemias. Lipids. 2021;56(3):259\u201368. https:\/\/doi.org\/10.1002\/lipd.12290.","journal-title":"Lipids"},{"issue":"2","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1253\/circj.CJ-19-0879","volume":"84","author":"G Benincasa","year":"2020","unstructured":"Benincasa G, Marfella R, Della Mura N, Schiano C, Napoli C. Strengths and opportunities of network medicine in cardiovascular diseases. Circ J. 2020;84(2):144\u201352. https:\/\/doi.org\/10.1253\/circj.CJ-19-0879.","journal-title":"Circ J"},{"key":"1033_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12471-017-0959-2","volume":"25","author":"SC Bergheanu","year":"2017","unstructured":"Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. Neth Hear J. 2017;25:231\u201342. https:\/\/doi.org\/10.1007\/s12471-017-0959-2.","journal-title":"Neth Hear J"},{"issue":"14","key":"1033_CR22","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.3390\/ijms26146950","volume":"26","author":"E Bezsonov","year":"2025","unstructured":"Bezsonov E, Chernyi N, Saruhanyan M, Shimchenko D, Bondar N, Gavrilova D, et al. Gene therapy approaches for atherosclerosis focusing on targeting lipid metabolism and inflammation. Int J Mol Sci. 2025;26(14):6950. https:\/\/doi.org\/10.3390\/ijms26146950.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cells14020131","volume":"14","author":"K Bonowicz","year":"2025","unstructured":"Bonowicz K, Jerka D, Piekarska K, Olagbaju J, Stapleton L, Shobowale M, et al. CRISPR-Cas9 in cardiovascular medicine: unlocking new potential for treatment. Cells. 2025;14(2):131. https:\/\/doi.org\/10.3390\/cells14020131.","journal-title":"Cells"},{"key":"1033_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2025.05.008","author":"G Bosco","year":"2025","unstructured":"Bosco G, Barbagallo FDG, Di Marco M, Scilletta S, Miano N, Esposto S, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Diseases. 2025. https:\/\/doi.org\/10.1016\/j.pcad.2025.05.008.","journal-title":"Prog Cardiovasc Diseases"},{"issue":"6","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/jcm12062444","volume":"12","author":"G Bosco","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, Lanzafame L, Di Pino A, Piro S, et al. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023;12(6):2444. https:\/\/doi.org\/10.3390\/jcm12062444.","journal-title":"J Clin Med"},{"issue":"2","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.chom.2023.01.009","volume":"31","author":"EM Brown","year":"2023","unstructured":"Brown EM, Clardy J, Xavier RJ. Gut microbiome lipid metabolism and its impact on host physiology. Cell Host Microbe. 2023;31(2):173\u201386. https:\/\/doi.org\/10.1016\/j.chom.2023.01.009.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"1033_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PW, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1033_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm16010001","volume":"16","author":"AR Canestrale","year":"2025","unstructured":"Canestrale AR, Kholia S, Dimuccio V, Herrera Sanchez MB. Targeted hepatic delivery of bioactive molecules via nanovesicles: recent developments and emerging directions. J Pers Med. 2025;16(1):1. https:\/\/doi.org\/10.3390\/jpm16010001.","journal-title":"J Pers Med"},{"issue":"4","key":"1033_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/metabo15040220","volume":"15","author":"E Caradonna","year":"2025","unstructured":"Caradonna E, Abate F, Schiano E, Paparella F, Ferrara F, Vanoli E, et al. Trimethylamine-N-Oxide (TMAO) as a rising-star metabolite: implications for human health. Metabolites. 2025;15(4):220. https:\/\/doi.org\/10.3390\/metabo15040220.","journal-title":"Metabolites"},{"issue":"12","key":"1033_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/pharmaceutics16121521","volume":"16","author":"L Catenacci","year":"2024","unstructured":"Catenacci L, Rossi R, Sechi F, Buonocore D, Sorrenti M, Perteghella S, et al. Effect of lipid nanoparticle physico-chemical properties and composition on their interaction with the immune system. Pharmaceutics. 2024;16(12):1521. https:\/\/doi.org\/10.3390\/pharmaceutics16121521.","journal-title":"Pharmaceutics"},{"issue":"11","key":"1033_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116022","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of probiotics on gut microbiota: an overview. Int J Mol Sci. 2024;25(11):6022. https:\/\/doi.org\/10.3390\/ijms25116022.","journal-title":"Int J Mol Sci"},{"key":"1033_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.crbiot.2023.100150","author":"S Chatterjee","year":"2023","unstructured":"Chatterjee S, Bhattacharya M, Lee SS, Chakraborty C. An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: current landscape. Curr Res Biotechnol. 2023. https:\/\/doi.org\/10.1016\/j.crbiot.2023.100150.","journal-title":"Curr Res Biotechnol"},{"issue":"3","key":"1033_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2024.01.028","volume":"32","author":"SPS Chia","year":"2024","unstructured":"Chia SPS, Pang JKS, Soh BS. Current RNA strategies in treating cardiovascular diseases. Mol Ther. 2024;32(3):580\u2013608. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.028.","journal-title":"Mol Ther"},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KG, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+ AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"issue":"1","key":"1033_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41434-020-00197-8","volume":"29","author":"MR Cring","year":"2022","unstructured":"Cring MR, Sheffield VC. Gene therapy and gene correction: targets, progress, and challenges for treating human diseases. Gene Ther. 2022;29(1):3\u201312. https:\/\/doi.org\/10.1038\/s41434-020-00197-8.","journal-title":"Gene Ther"},{"issue":"3","key":"1033_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14728222.2025.2482545","volume":"29","author":"L Da Dalt","year":"2025","unstructured":"Da Dalt L, Baragetti A, Norata GD. Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies. Expert Opin Ther Targets. 2025;29(3):137\u201357. https:\/\/doi.org\/10.1080\/14728222.2025.2482545.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"1033_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/pharmaceutics16040461","volume":"16","author":"R Dankar","year":"2024","unstructured":"Dankar R, Wehbi J, Refaat MM. Tailoring treatment in cardiovascular diseases: the role of targeted therapies. Pharmaceutics. 2024;16(4):461. https:\/\/doi.org\/10.3390\/pharmaceutics16040461.","journal-title":"Pharmaceutics"},{"issue":"10","key":"1033_CR39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/biomedicines10051090","volume":"2022","author":"E Dayar","year":"2022","unstructured":"Dayar E, Pechanova O. Targeted strategy in lipid-lowering therapy. Biomedicines. 2022;2022(10):1090. https:\/\/doi.org\/10.3390\/biomedicines10051090.","journal-title":"Biomedicines"},{"issue":"3","key":"1033_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/gutjnl-2019-318320","volume":"69","author":"P de Groot","year":"2020","unstructured":"de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut. 2020;69(3):502\u201312. https:\/\/doi.org\/10.1136\/gutjnl-2019-318320.","journal-title":"Gut"},{"issue":"8","key":"1033_CR41","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28(8):1759\u201371. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.015.","journal-title":"Mol Ther"},{"issue":"21","key":"1033_CR42","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MR, Huntley MH, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. New England J Med. 2019;381(21):2043\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1910437.","journal-title":"New England J Med."},{"issue":"6","key":"1033_CR43","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.cell.2021.01.015","volume":"184","author":"JC Denny","year":"2021","unstructured":"Denny JC, Collins FS. Precision medicine in 2030: seven ways to transform healthcare. Cell. 2021;184(6):1415\u20139. https:\/\/doi.org\/10.1016\/j.cell.2021.01.015.","journal-title":"Cell"},{"issue":"14","key":"1033_CR44","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","volume":"48","author":"K Deprey","year":"2020","unstructured":"Deprey K, Batistatou N, Kritzer JA. A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics. Nucleic Acids Res. 2020;48(14):7623\u201339. https:\/\/doi.org\/10.1093\/nar\/gkaa576.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1033_CR45","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.7150\/thno.89380","volume":"14","author":"BP Dhungel","year":"2024","unstructured":"Dhungel BP, Winburn I, da Fonseca Pereira C, Huang K, Chhabra A, Rasko JE. Understanding AAV vector immunogenicity: from particle to patient. Theranostics. 2024;14(3):1260. https:\/\/doi.org\/10.7150\/thno.89380.","journal-title":"Theranostics"},{"issue":"6","key":"1033_CR46","doi-asserted-by":"publisher","first-page":"e13836","DOI":"10.1111\/cts.13836","volume":"17","author":"R Dingman","year":"2024","unstructured":"Dingman R, Bihorel S, Gusarova V, Mendell J, Pordy R. Evinacumab: mechanism of action, clinical, and translational science. Clin Trans Sci. 2024;17(6):e13836. https:\/\/doi.org\/10.1111\/cts.13836.","journal-title":"Clin Trans Sci"},{"issue":"1","key":"1033_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7(1):265. https:\/\/doi.org\/10.1038\/s41392-022-01125-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1033_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13237-024-00480-8","volume":"67","author":"S Duddu","year":"2024","unstructured":"Duddu S, Chakrabarti R, Sharma P, Gupta D, Shukla PC. Gene editing and therapy in acquired and inherited cardiovascular disorders. Nucleus. 2024;67(1):237\u201350. https:\/\/doi.org\/10.1007\/s13237-024-00480-8.","journal-title":"Nucleus"},{"key":"1033_CR49","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","volume":"159","author":"OM Elsharkasy","year":"2020","unstructured":"Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev. 2020;159:332\u201343. https:\/\/doi.org\/10.1016\/j.addr.2020.04.004.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"1033_CR50","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/ehjqcco\/qcae099","volume":"11","author":"I Engebretsen","year":"2025","unstructured":"Engebretsen I, \u00d8degaard KM, Halvorsen S, Bugge C, Kristiansen IS, St\u00f8vring H, et al. Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. Eur Heart J Qual Care Clin Outcomes. 2025;11(8):1290\u2013300. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae099.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1033_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/frobt.2024.1444763","volume":"11","author":"M Ennab","year":"2024","unstructured":"Ennab M, Mcheick H. Enhancing interpretability and accuracy of AI models in healthcare: a comprehensive review on challenges and future directions. Front Robot AI. 2024;11:1444763. https:\/\/doi.org\/10.3389\/frobt.2024.1444763.","journal-title":"Front Robot AI"},{"issue":"14","key":"1033_CR52","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3390\/jcm14144984","volume":"14","author":"C Escobar-Cervantes","year":"2025","unstructured":"Escobar-Cervantes C, Salda\u00f1a-Garc\u00eda J, Torremocha-L\u00f3pez A, Contreras-Lorenzo C, Lara-Garc\u00eda A, Canales-Mu\u00f1oz L, et al. Integrating new technologies in lipidology: a comprehensive review. J Clin Med. 2025;14(14):4984. https:\/\/doi.org\/10.3390\/jcm14144984.","journal-title":"J Clin Med"},{"issue":"1","key":"1033_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13063-022-06086-2","volume":"23","author":"L Fan","year":"2022","unstructured":"Fan L, Ren J, Chen Y, Wang Y, Guo Z, Bu P, et al. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. Trials. 2022;23(1):178. https:\/\/doi.org\/10.1186\/s13063-022-06086-2.","journal-title":"Trials"},{"issue":"1","key":"1033_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","volume":"19","author":"Y Fan","year":"2021","unstructured":"Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55\u201371. https:\/\/doi.org\/10.1038\/s41579-020-0433-9.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"1033_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/nu15010228","volume":"15","author":"B Flaig","year":"2023","unstructured":"Flaig B, Garza R, Singh B, Hamamah S, Covasa M. Treatment of dyslipidemia through targeted therapy of gut microbiota. Nutrients. 2023;15(1):228. https:\/\/doi.org\/10.3390\/nu15010228.","journal-title":"Nutrients"},{"issue":"10","key":"1033_CR56","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069\u201378. https:\/\/doi.org\/10.1001\/jamacardio.2017.2762.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1033_CR57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822\u20136. https:\/\/doi.org\/10.1038\/nbt.2623.","journal-title":"Nat Biotechnol"},{"key":"1033_CR58","doi-asserted-by":"publisher","DOI":"10.33218\/001c.94464","author":"P Gao","year":"2024","unstructured":"Gao P. Advancements in lipid nanoparticle technologies for precision targeting in therapeutic delivery. Precis Nanomed. 2024. https:\/\/doi.org\/10.33218\/001c.94464.","journal-title":"Precis Nanomed"},{"issue":"2","key":"1033_CR59","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz039","volume":"4","author":"SS Ghosh","year":"2020","unstructured":"Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4(2):bvz039. https:\/\/doi.org\/10.1210\/jendso\/bvz039.","journal-title":"J Endocr Soc"},{"issue":"6","key":"1033_CR60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"New England J Med"},{"issue":"7","key":"1033_CR61","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. New England J Med. 2017;377(7):633\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1701131.","journal-title":"New England J Med"},{"key":"1033_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"35","key":"1033_CR63","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1093\/eurheartj\/ehaf411","volume":"46","author":"C Gurevitz","year":"2025","unstructured":"Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, et al. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J. 2025;46(35):3420\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf411.","journal-title":"Eur Heart J"},{"issue":"3","key":"1033_CR64","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","volume":"124","author":"RA Hegele","year":"2019","unstructured":"Hegele RA, Tsimikas S. Lipid-lowering agents: targets beyond PCSK9. Circ Res. 2019;124(3):386\u2013404. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313171.","journal-title":"Circ Res"},{"key":"1033_CR65","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S517492","author":"Y Herdiana","year":"2025","unstructured":"Herdiana Y, Levita J, Jiranusornkul S. Chitosan-based nanoparticles targeted delivery system: in treatment approach for dyslipidemia. Int J Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/IJN.S517492.","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"1033_CR66","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","volume":"16","author":"IK Herrmann","year":"2021","unstructured":"Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748\u201359. https:\/\/doi.org\/10.1038\/s41565-021-00931-2.","journal-title":"Nat Nanotechnol"},{"issue":"21","key":"1033_CR67","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","volume":"70","author":"MA Hlatky","year":"2017","unstructured":"Hlatky MA, Kazi DS. PCSK9 inhibitors: economics and policy. J Am Coll Cardiol. 2017;70(21):2677\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.001.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1033_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11883-024-01198-3","volume":"26","author":"M Hoekstra","year":"2024","unstructured":"Hoekstra M, Van Eck M. Gene editing for the treatment of hypercholesterolemia. Curr Atheroscler Rep. 2024;26(5):139\u201346. https:\/\/doi.org\/10.1007\/s11883-024-01198-3.","journal-title":"Curr Atheroscler Rep"},{"key":"1033_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101436","author":"M Hosseini-Kharat","year":"2025","unstructured":"Hosseini-Kharat M, Bremmell KE, Prestidge CA. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol Ther Methods Clin Dev. 2025. https:\/\/doi.org\/10.1016\/j.omtm.2025.101436.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"1033_CR70","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"2","key":"1033_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/wics.70030","volume":"17","author":"Y Huang","year":"2025","unstructured":"Huang Y, Cho M, Chakraborty S, Dey T. Variable selection for prediction in clinical research. Wiley Interdiscip Rev Comput Stat. 2025;17(2):e70030. https:\/\/doi.org\/10.1002\/wics.70030.","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"issue":"4","key":"1033_CR72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5551\/jat.52407","volume":"27","author":"T Infante","year":"2020","unstructured":"Infante T, Del Viscovo L, De Rimini ML, Padula S, Caso P, Napoli C. Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. J Atheroscler Thromb. 2020;27(4):279\u2013302. https:\/\/doi.org\/10.5551\/jat.52407.","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"1033_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70174","volume":"7","author":"BM Jeswani","year":"2024","unstructured":"Jeswani BM, Sharma S, Rathore SS, Nazir A, Bhatheja R, Kapoor K. PCSK9 inhibitors: the evolving future. Health Sci Rep. 2024;7(11):e70174. https:\/\/doi.org\/10.1002\/hsr2.70174.","journal-title":"Health Sci Rep"},{"issue":"6","key":"1033_CR74","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10557-020-07082-x","volume":"35","author":"X Jia","year":"2021","unstructured":"Jia X, Liu J, Mehta A, Ballantyne CM, Virani SS. Lipid-lowering biotechnological drugs: from monoclonal antibodies to antisense therapies-a clinical perspective. Cardiovasc Drugs Ther. 2021;35(6):1269\u201379. https:\/\/doi.org\/10.1007\/s10557-020-07082-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1033_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.634780","volume":"11","author":"X Jia","year":"2021","unstructured":"Jia X, Xu W, Zhang L, Li X, Wang R, Wu S. Impact of gut microbiota and microbiota-related metabolites on hyperlipidemia. Front Cell Infect Microbiol. 2021;11:634780. https:\/\/doi.org\/10.3389\/fcimb.2021.634780.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"1033_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202305300","volume":"36","author":"Y Jia","year":"2024","unstructured":"Jia Y, Wang X, Li L, Li F, Zhang J, Liang XJ. Lipid nanoparticles optimized for targeting and release of nucleic acid. Adv Mater. 2024;36(4):2305300. https:\/\/doi.org\/10.1002\/adma.202305300.","journal-title":"Adv Mater"},{"issue":"9","key":"1033_CR77","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40273-020-00948-w","volume":"38","author":"N Kam","year":"2020","unstructured":"Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: a cost-effectiveness analysis. Pharmacoeconomics. 2020;38(9):1007\u201320. https:\/\/doi.org\/10.1007\/s40273-020-00948-w.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1033_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70079","volume":"55","author":"M Kanbay","year":"2025","unstructured":"Kanbay M, Ozbek L, Guldan M, Yilmaz ZY, Ortiz A, Mallamaci F, et al. siRNA-based therapeutics for lipoprotein (a) lowering: a path toward precision cardiovascular medicine. Eur J Clin Invest. 2025;55(9):e70079. https:\/\/doi.org\/10.1111\/eci.70079.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"1033_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000547334","volume":"35","author":"MA Karimi","year":"2026","unstructured":"Karimi MA, Paryan M, Behrouzian Fard G, Sadeghian H, Zarrinfar H, Hosseini Bafghi M. Challenges and opportunities in the application of CRISPR-Cas9: a review on genomic editing and therapeutic potentials. Med Princ Pract. 2026;35(1):1\u201317. https:\/\/doi.org\/10.1159\/000547334.","journal-title":"Med Princ Pract"},{"issue":"6","key":"1033_CR80","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/19490976.2020.1764309","volume":"11","author":"K Ka\u017amierczak-Siedlecka","year":"2020","unstructured":"Ka\u017amierczak-Siedlecka K, Daca A, Fic M, van de Wetering T, Folwarski M, Makarewicz W. Therapeutic methods of gut microbiota modification in colorectal cancer management-fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes. 2020;11(6):1518\u201330. https:\/\/doi.org\/10.1080\/19490976.2020.1764309.","journal-title":"Gut Microbes"},{"issue":"6","key":"1033_CR81","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1053\/j.gastro.2020.08.039","volume":"159","author":"CR Kelly","year":"2020","unstructured":"Kelly CR, Laine LA, Wu GD. Monitoring fecal microbiota transplantation practice in a rapidly evolving health and regulatory environment. Gastroenterology. 2020;159(6):2004. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.039.","journal-title":"Gastroenterology"},{"issue":"8","key":"1033_CR82","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36(8):765\u201371. https:\/\/doi.org\/10.1038\/nbt.4192.","journal-title":"Nat Biotechnol"},{"issue":"25","key":"1033_CR83","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/eurheartj\/ehz056","volume":"40","author":"C Krittanawong","year":"2019","unstructured":"Krittanawong C, Johnson KW, Rosenson RS, Wang Z, Aydar M, Baber U, et al. Deep learning for cardiovascular medicine: a practical primer. Eur Heart J. 2019;40(25):2058\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehz056.","journal-title":"Eur Heart J"},{"issue":"3","key":"1033_CR84","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.072","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, Van Der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146\u201357. https:\/\/doi.org\/10.1089\/nat.2018.072.","journal-title":"Nucleic Acid Ther"},{"key":"1033_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118629","author":"JA Laukkanen","year":"2024","unstructured":"Laukkanen JA, Pohjonen T, Kurl S, Kunutsor SK. Associations of high-density lipoprotein cholesterol levels with the presence and severity of coronary atherosclerosis. Atherosclerosis. 2024. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118629.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1033_CR86","doi-asserted-by":"publisher","first-page":"H1227","DOI":"10.1152\/ajpheart.00612.2020","volume":"319","author":"CV Lewis","year":"2020","unstructured":"Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020;319(6):H1227\u201333. https:\/\/doi.org\/10.1152\/ajpheart.00612.2020.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1033_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.911429","volume":"13","author":"ZF Li","year":"2022","unstructured":"Li ZF, Wu NQ. The progression of treatment for refractory hypercholesterolemia: focus on the prospect of gene therapy. Front Genet. 2022;13:911429. https:\/\/doi.org\/10.3389\/fgene.2022.911429.","journal-title":"Front Genet"},{"key":"1033_CR88","doi-asserted-by":"publisher","first-page":"827107","DOI":"10.3389\/fendo.2022.827107","volume":"13","author":"F Liang","year":"2022","unstructured":"Liang F, Lu X, Deng Z, Zhong HJ, Zhang W, Li Q, et al. Effect of washed microbiota transplantation on patients with dyslipidemia in south China. Front Endocrinol. 2022;13:827107. https:\/\/doi.org\/10.3389\/fendo.2022.827107.","journal-title":"Front Endocrinol"},{"key":"1033_CR89","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S512207","author":"J Liu","year":"2025","unstructured":"Liu J, Ge P, Luo Y, Sun Z, Luo X, Li H, et al. Decoding TMAO in the gut-organ axis: from biomarkers and cell death mechanisms to therapeutic horizons. Drug Design, Develop Ther. 2025a . https:\/\/doi.org\/10.2147\/DDDT.S512207","journal-title":"Drug Design, Develop Ther"},{"issue":"4","key":"1033_CR90","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0104","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of gut microbiota metabolites, current status and future perspectives. Aging Dis. 2022;13(4):1106. https:\/\/doi.org\/10.14336\/AD.2022.0104.","journal-title":"Aging Dis"},{"issue":"1","key":"1033_CR91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ehjdh\/ztae080","volume":"6","author":"T Liu","year":"2025","unstructured":"Liu T, Krentz A, Lu L, Curcin V. Machine learning based prediction models for cardiovascular disease risk using electronic health records data: systematic review and meta-analysis. Eur Heart J Digit Health. 2025b;6(1):7\u201322. . https:\/\/doi.org\/10.1093\/ehjdh\/ztae080","journal-title":"Eur Heart J Digit Health"},{"key":"1033_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2020.07.004","volume":"82","author":"Z Liu","year":"2020","unstructured":"Liu Z, de Vries B, Gerritsen J, Smidt H, Zoetendal EG. Microbiome-based stratification to guide dietary interventions to improve human health. Nutr Res. 2020;82:1\u201310. https:\/\/doi.org\/10.1016\/j.nutres.2020.07.004.","journal-title":"Nutr Res"},{"issue":"1","key":"1033_CR93","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","volume":"2","author":"SM Lundberg","year":"2020","unstructured":"Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, et al. From local explanations to global understanding with explainable AI for trees. Nat Mach Intell. 2020;2(1):56\u201367. https:\/\/doi.org\/10.1038\/s42256-019-0138-9.","journal-title":"Nat Mach Intell"},{"issue":"1","key":"1033_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00218-7","volume":"5","author":"Z Ma","year":"2024","unstructured":"Ma Z, Zhong J, Tu W, Li S, Chen J. The functions of apolipoproteins and lipoproteins in health and disease. Mol Biomed. 2024;5(1):53. https:\/\/doi.org\/10.1186\/s43556-024-00218-7.","journal-title":"Mol Biomed"},{"key":"1033_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1675209","volume":"16","author":"SK Makkar","year":"2025","unstructured":"Makkar SK. Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Front Genet. 2025;16:1675209. https:\/\/doi.org\/10.3389\/fgene.2025.1675209.","journal-title":"Front Genet"},{"issue":"14","key":"1033_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144160","volume":"13","author":"BS Mansfield","year":"2024","unstructured":"Mansfield BS, Mohamed F, Larouche M, Raal FJ. The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias. J Clin Med. 2024;13(14):4160. https:\/\/doi.org\/10.3390\/jcm13144160.","journal-title":"J Clin Med"},{"key":"1033_CR97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2021.08.009","volume":"349","author":"V Marco-Bened\u00ed","year":"2022","unstructured":"Marco-Bened\u00ed V, Cenarro A, Laclaustra M, Larrea-Sebal A, Jarauta E, Lamiquiz-Moneo I, et al. Lipoprotein (a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis. 2022;349:211\u20138.","journal-title":"Atherosclerosis"},{"key":"1033_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-1776-8","volume":"17","author":"L Miao","year":"2019","unstructured":"Miao L, Yin RX, Pan SL, Yang S, Yang DZ, Lin WX. Circulating miR-3659 may be a potential biomarker of dyslipidemia in patients with obesity. J Transl Med. 2019;17:1\u201310. https:\/\/doi.org\/10.1186\/s12967-019-1776-8.","journal-title":"J Transl Med"},{"issue":"2","key":"1033_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1033_CR100","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2017.01.011","volume":"246","author":"S Mitragotri","year":"2017","unstructured":"Mitragotri S, Lammers T, Bae YH, Schwendeman S, De Smedt SC, Leroux JC, et al. Drug delivery research for the future: expanding the nano horizons and beyond. J Controlled Release. 2017;246:183\u20134. https:\/\/doi.org\/10.1016\/j.jconrel.2017.01.011.","journal-title":"J Controlled Release"},{"issue":"7859","key":"1033_CR101","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334. https:\/\/doi.org\/10.1038\/s41586-021-03534-y.","journal-title":"Nature"},{"issue":"1","key":"1033_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19261-8","volume":"24","author":"S Naderian","year":"2024","unstructured":"Naderian S, Nikniaz Z, Farhangi MA, Nikniaz L, Sama-Soltani T, Rostami P. Predicting dyslipidemia incidence: unleashing machine learning algorithms on Lifestyle Promotion Project data. BMC Public Health. 2024;24(1):1777. https:\/\/doi.org\/10.1186\/s12889-024-19261-8.","journal-title":"BMC Public Health"},{"issue":"4","key":"1033_CR103","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/011573403X299265240405080030","volume":"20","author":"M Narkhede","year":"2024","unstructured":"Narkhede M, Pardeshi A, Bhagat R, Dharme G. Review on emerging therapeutic strategies for managing cardiovascular disease. Curr Cardiol Rev. 2024;20(4):86\u2013100. https:\/\/doi.org\/10.2174\/011573403X299265240405080030.","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"1033_CR104","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2012","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2012;40(1):195. https:\/\/doi.org\/10.1016\/j.pop.2012.11.003.","journal-title":"Prim Care"},{"issue":"8","key":"1033_CR105","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"15","key":"1033_CR106","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"New Engl J Med"},{"issue":"20","key":"1033_CR107","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa221102","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease. New Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa221102.","journal-title":"New Engl J Med"},{"issue":"6","key":"1033_CR108","doi-asserted-by":"publisher","first-page":"936","DOI":"10.17305\/bb.2023.8893","volume":"23","author":"YH Oktaviono","year":"2023","unstructured":"Oktaviono YH, Lamara AD, Saputra PBT, Arnindita JN, Pasahari D, Saputra ME, et al. The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: a literature review. Biomolecules Biomed. 2023;23(6):936. https:\/\/doi.org\/10.17305\/bb.2023.8893.","journal-title":"Biomolecules Biomed"},{"issue":"1","key":"1033_CR109","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10557-020-07017-6","volume":"35","author":"C Parolini","year":"2021","unstructured":"Parolini C. Biotechnology approaches for the treatment of dyslipidemia. Cardiovasc Drugs Ther. 2021;35(1):167\u201383. https:\/\/doi.org\/10.1007\/s10557-020-07017-6.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"17","key":"1033_CR110","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.3390\/jcm14176034","volume":"14","author":"S Patel","year":"2025","unstructured":"Patel S, Huang M, Miliara S. Understanding treatment adherence in chronic diseases: challenges, consequences, and strategies for improvement. J Clin Med. 2025;14(17):6034. https:\/\/doi.org\/10.3390\/jcm14176034.","journal-title":"J Clin Med"},{"issue":"13","key":"1033_CR111","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/nu16132023","volume":"16","author":"E Pokushalov","year":"2024","unstructured":"Pokushalov E, Ponomarenko A, Smith J, Johnson M, Garcia C, Pak I, et al. Efficacy of AI-guided (GenAISTM) dietary supplement prescriptions versus traditional methods for lowering LDL Cholesterol: a randomized parallel-group pilot study. Nutrients. 2024;16(13):2023. https:\/\/doi.org\/10.3390\/nu16132023.","journal-title":"Nutrients"},{"issue":"20","key":"1033_CR112","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3390\/cells12202466","volume":"12","author":"G Preta","year":"2023","unstructured":"Preta G. Development of new genome editing tools for the treatment of hyperlipidemia. Cells. 2023;12(20):2466. https:\/\/doi.org\/10.3390\/cells12202466.","journal-title":"Cells"},{"key":"1033_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2020.06.018","volume":"83","author":"IM Proen\u00e7a","year":"2020","unstructured":"Proen\u00e7a IM, Allegretti JR, Bernardo WM, de Moura DT, Neto AMP, Matsubayashi CO, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020;83:1\u201314. https:\/\/doi.org\/10.1016\/j.nutres.2020.06.018.","journal-title":"Nutr Res"},{"key":"1033_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107086","volume":"201","author":"M Puccetti","year":"2024","unstructured":"Puccetti M, Pariano M, Schoubben A, Giovagnoli S, Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol Res. 2024;201:107086. https:\/\/doi.org\/10.1016\/j.phrs.2024.107086.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1033_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065806","volume":"24","author":"G Querio","year":"2023","unstructured":"Querio G, Antoniotti S, Geddo F, Levi R, Gallo MP. Modulation of endothelial function by TMAO, a gut microbiota-derived metabolite. Int J Mol Sci. 2023;24(6):5806. https:\/\/doi.org\/10.3390\/ijms24065806.","journal-title":"Int J Mol Sci"},{"key":"1033_CR116","doi-asserted-by":"publisher","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros M J, ORION-11 Investigators. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u20135057. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615","DOI":"10.1093\/eurheartj\/ehac615"},{"issue":"8","key":"1033_CR117","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"issue":"8","key":"1033_CR118","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl T, Dennis MK, Lin PJ, Oka R, Witzigmann D, Villiger L, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39(8):949\u201357. https:\/\/doi.org\/10.1038\/s41587-021-00933-4.","journal-title":"Nat Biotechnol"},{"issue":"18","key":"1033_CR119","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"New Engl J Med"},{"key":"1033_CR120","doi-asserted-by":"publisher","first-page":"109370","DOI":"10.1016\/j.compeleceng.2024.109370","volume":"118","author":"Z Sadeghi","year":"2024","unstructured":"Sadeghi Z, Alizadehsani R, Cifci MA, Kausar S, Rehman R, Mahanta P, et al. A review of explainable artificial intelligence in healthcare. Comput Electric Eng. 2024;118:109370. https:\/\/doi.org\/10.1016\/j.compeleceng.2024.109370.","journal-title":"Comput Electric Eng"},{"key":"1033_CR121","doi-asserted-by":"publisher","first-page":"100701","DOI":"10.1016\/j.ajpc.2024.100701","volume":"19","author":"M Safarova","year":"2024","unstructured":"Safarova M, Bimal T, Soffer DE, Hirsh B, Shapiro MD, Mintz G, et al. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. American J Prevent Cardiol. 2024;19:100701. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100701.","journal-title":"American J Prevent Cardiol"},{"issue":"19","key":"1033_CR122","doi-asserted-by":"publisher","first-page":"2207512","DOI":"10.1002\/advs.202207512","volume":"10","author":"DK Sahel","year":"2023","unstructured":"Sahel DK, Vora LK, Saraswat A, Sharma S, Monpara J, D\u2019Souza AA, et al. CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective. Adv Sci. 2023;10(19):2207512. https:\/\/doi.org\/10.1002\/advs.202207512.","journal-title":"Adv Sci"},{"key":"1033_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102487","volume":"63","author":"T Sahu","year":"2021","unstructured":"Sahu T, Ratre YK, Chauhan S, Bhaskar LVKS, Nair MP, Verma HK. Nanotechnology based drug delivery system: current strategies and emerging therapeutic potential for medical science. J Drug Deliv Sci Technol. 2021;63:102487. https:\/\/doi.org\/10.1016\/j.jddst.2021.102487.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1033_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2021.102480","volume":"40","author":"TA Salaheldin","year":"2022","unstructured":"Salaheldin TA, Godugu K, Bharali DJ, Fujioka K, Elshourbagy N, Mousa SA. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia. Nanomedicine (Lond). 2022;40:102480. https:\/\/doi.org\/10.1016\/j.nano.2021.102480.","journal-title":"Nanomedicine (Lond)"},{"issue":"5","key":"1033_CR125","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.29303\/jppipa.v10i5.6237","volume":"10","author":"IPBA Saputra","year":"2024","unstructured":"Saputra IPBA, Arjita IPD. The potential of flavonoid derivative compounds as inhibitors of the HMG-CoA reductase enzyme for candidate of hypercholesterolemia drugs. J Penelit Pendidik IPA. 2024;10(5):2286\u201393. https:\/\/doi.org\/10.29303\/jppipa.v10i5.6237.","journal-title":"J Penelit Pendidik IPA"},{"key":"1033_CR126","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-030-16391-4","volume-title":"Precision medicine in cancer therapy","author":"NJ Schork","year":"2019","unstructured":"Schork NJ. Artificial intelligence and personalized medicine. In: Precision medicine in cancer therapy. Cham: Springer International Publishing; 2019. p. 265\u201383. https:\/\/doi.org\/10.1007\/978-3-030-16391-4."},{"issue":"22","key":"1033_CR127","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"New Engl J Med"},{"issue":"4","key":"1033_CR128","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","volume":"15","author":"F Sebastiani","year":"2021","unstructured":"Sebastiani F, Yanez Arteta M, Lerche M, Porcar L, Lang C, Bragg RA, et al. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles. ACS Nano. 2021;15(4):6709\u201322. https:\/\/doi.org\/10.1021\/acsnano.0c10064.","journal-title":"ACS Nano"},{"issue":"3","key":"1033_CR129","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43(3):558\u201382. https:\/\/doi.org\/10.1210\/endrev\/bnab035.","journal-title":"Endocr Rev"},{"issue":"9","key":"1033_CR130","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.3390\/ijms26094420","volume":"26","author":"A Seijas","year":"2025","unstructured":"Seijas A, Cora D, Novo M, Al-Soufi W, S\u00e1nchez L, Arana \u00c1J. CRISPR\/Cas9 delivery systems to enhance gene editing efficiency. Int J Mol Sci. 2025;26(9):4420. https:\/\/doi.org\/10.3390\/ijms26094420.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1033_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/apm.70100","volume":"133","author":"N Sharma","year":"2025","unstructured":"Sharma N, Roy S. Dysbiosis and dyslipidemia: unraveling the microbiome\u2019s role in lipid metabolism and therapeutic potential. APMIS. 2025;133(12):e70100. https:\/\/doi.org\/10.1111\/apm.70100.","journal-title":"APMIS"},{"issue":"12","key":"1033_CR132","doi-asserted-by":"publisher","first-page":"14","DOI":"10.65336\/WJAMS.2025.21203","volume":"2","author":"AM Sikkander","year":"2025","unstructured":"Sikkander AM, Rodrigues JJ, Meena M, Abuelmakarem HS. AI-driven genomic biomarker discovery for precision diagnosis and personalized treatment. World J Appl Med Sci. 2025;2(12):14\u201323. https:\/\/doi.org\/10.65336\/WJAMS.2025.21203.","journal-title":"World J Appl Med Sci"},{"issue":"1","key":"1033_CR133","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12944-024-02330-7","volume":"23","author":"P Simonen","year":"2024","unstructured":"Simonen P, Nylund L, Vartiainen E, Kovanen PT, Strandberg TE, \u00d6\u00f6rni K, et al. Heart-healthy diets including phytostanol ester consumption to reduce the risk of atherosclerotic cardiovascular diseases: a clinical review. Lipids Health Disease. 2024;23(1):341. https:\/\/doi.org\/10.1186\/s12944-024-02330-7.","journal-title":"Lipids Health Disease"},{"issue":"12","key":"1033_CR134","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11886-020-01427-6","volume":"22","author":"D Sinning","year":"2020","unstructured":"Sinning D, Landmesser U. Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep. 2020;22(12):176. https:\/\/doi.org\/10.1007\/s11886-020-01427-6.","journal-title":"Curr Cardiol Rep"},{"key":"1033_CR135","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Control Release. 2024;372:113\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.023.","journal-title":"J Control Release"},{"issue":"3","key":"1033_CR136","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109\u201318. https:\/\/doi.org\/10.1089\/nat.2018.0736.","journal-title":"Nucleic Acid Ther"},{"key":"1033_CR137","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ateroskleroz.2023.01.010","volume":"368","author":"S Stankov","year":"2023","unstructured":"Stankov S, Cuchel M. Gene editing for dyslipidemias: new tools to \u201ccut\u201d lipids. Atherosclerosis. 2023;368:14\u201324. https:\/\/doi.org\/10.1016\/j.ateroskleroz.2023.01.010.","journal-title":"Atherosclerosis"},{"key":"1033_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2026.107493","author":"PG Steg","year":"2026","unstructured":"Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, et al. Design of VICTORION-2 Prevent: a randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026. https:\/\/doi.org\/10.1016\/j.ahj.2026.107493.","journal-title":"Am Heart J"},{"issue":"5","key":"1033_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1379","volume":"10","author":"G Stiglic","year":"2020","unstructured":"Stiglic G, Kocbek P, Fijacko N, Zitnik M, Verbert K, Cilar L. Interpretability of machine learning-based prediction models in healthcare. Wiley Interdiscip Rev Data Mining Knowl Discov. 2020;10(5):e1379. https:\/\/doi.org\/10.1002\/widm.1379.","journal-title":"Wiley Interdiscip Rev Data Mining Knowl Discov"},{"key":"1033_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101470","author":"D Stone","year":"2025","unstructured":"Stone D, Takeuchi R, Dulin H, Loprieno MA, Strongin DE, Sathees S, et al. Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice. Mol Ther Methods Clin Develop. 2025. https:\/\/doi.org\/10.1016\/j.omtm.2025.101470.","journal-title":"Mol Ther Methods Clin Develop"},{"issue":"1-2","key":"1033_CR141","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbrc.2016.11.017","volume":"481","author":"X Sun","year":"2016","unstructured":"Sun X, Jiao X, Ma Y, Liu Y, Zhang L, He Y, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun. 2016;481(1\u20132):63\u201370. https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.017.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1033_CR142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/medicina58010084","volume":"58","author":"S Tkach","year":"2022","unstructured":"Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Boccuto L, et al. Current status and future therapeutic options for fecal microbiota transplantation. Medicina. 2022;58(1):84. https:\/\/doi.org\/10.3390\/medicina58010084.","journal-title":"Medicina"},{"key":"1033_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14989","author":"L Torella","year":"2024","unstructured":"Torella L, Santana\u2010Gonzalez N, Zabaleta N, Gonzalez Aseguinolaza G. Gene editing in liver diseases. FEBS Lett. 2024. https:\/\/doi.org\/10.1002\/1873-3468.14989.","journal-title":"FEBS Lett"},{"issue":"2","key":"1033_CR144","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33(2):187\u201397. https:\/\/doi.org\/10.1038\/nbt.3117.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1033_CR145","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein (a) reduction in persons with cardiovascular disease. New Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"New Engl J Med"},{"issue":"1","key":"1033_CR146","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymthe.2021.06.003","volume":"30","author":"M van Hees","year":"2022","unstructured":"van Hees M, Slott S, Hansen AH, Kim HS, Ji HP, Astakhova K. New approaches to moderate CRISPR-Cas9 activity: addressing issues of cellular uptake and endosomal escape. Mol Ther. 2022;30(1):32\u201346. https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.003.","journal-title":"Mol Ther"},{"key":"1033_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1466337","volume":"15","author":"O Vasileva","year":"2024","unstructured":"Vasileva O, Zaborova O, Shmykov B, Ivanov R, Reshetnikov V. Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics. Front Pharmacol. 2024;15:1466337. https:\/\/doi.org\/10.3389\/fphar.2024.1466337.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1033_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325330","volume":"20","author":"QD Vo","year":"2025","unstructured":"Vo QD. Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: a scoping review. PLoS ONE. 2025;20(6):e0325330. https:\/\/doi.org\/10.1371\/journal.pone.0325330.","journal-title":"PLoS ONE"},{"issue":"15","key":"1033_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158074","volume":"22","author":"M Vourakis","year":"2021","unstructured":"Vourakis M, Mayer G, Rousseau G. The role of gut microbiota on cholesterol metabolism in atherosclerosis. Int J Mol Sci. 2021;22(15):8074. https:\/\/doi.org\/10.3390\/ijms22158074.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1033_CR150","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.gendis.2020.11.003","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Liu Z, Shao J, Jiang M, Lu X, Lin L, et al. Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants. Genes & Diseases. 2022;9(2):370\u201380. https:\/\/doi.org\/10.1016\/j.gendis.2020.11.003.","journal-title":"Genes & Diseases"},{"issue":"1","key":"1033_CR151","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12967-025-06924-2","volume":"23","author":"X Wang","year":"2025","unstructured":"Wang X, Tian Z, Wang M, Cai X, Yang S, Zeng J, et al. Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines. J Transl Med. 2025;23(1):893. https:\/\/doi.org\/10.1186\/s12967-025-06924-2.","journal-title":"J Transl Med"},{"issue":"7","key":"1033_CR152","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/bios14070356","volume":"14","author":"T Wasilewski","year":"2024","unstructured":"Wasilewski T, Kamysz W, G\u0119bicki J. AI-assisted detection of biomarkers by sensors and biosensors for early diagnosis and monitoring. Biosensors (Basel). 2024;14(7):356. https:\/\/doi.org\/10.3390\/bios14070356.","journal-title":"Biosensors (Basel)"},{"issue":"27","key":"1033_CR153","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1093\/eurheartj\/ehae321","volume":"45","author":"GF Watts","year":"2024","unstructured":"Watts GF, Tamehri Zadeh SS, Chan DC. ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab. Eur Heart J. 2024;45(27):2435\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehae321.","journal-title":"Eur Heart J"},{"issue":"4","key":"1033_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174944","volume":"12","author":"SF Weng","year":"2017","unstructured":"Weng SF, Reps J, Kai J, Garibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLoS ONE. 2017;12(4):e0174944. https:\/\/doi.org\/10.1371\/journal.pone.0174944.","journal-title":"PLoS ONE"},{"key":"1033_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/198175","author":"K Werengowska-Cie\u0107wierz","year":"2015","unstructured":"Werengowska-Cie\u0107wierz K, Wi\u015bniewski M, Terzyk AP, Furmaniak S. The chemistry of bioconjugation in nanoparticles\u2010based drug delivery system. Adv Condens Matter Phys. 2015. https:\/\/doi.org\/10.1155\/2015\/198175.","journal-title":"Adv Condens Matter Phys"},{"issue":"9","key":"1033_CR156","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41591-019-0548-6","volume":"25","author":"J Wiens","year":"2019","unstructured":"Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337\u201340. https:\/\/doi.org\/10.1038\/s41591-019-0548-6.","journal-title":"Nat Med"},{"issue":"5","key":"1033_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"issue":"2","key":"1033_CR158","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/pharmaceutics15020323","volume":"15","author":"\u0141 Wo\u0142owiec","year":"2023","unstructured":"Wo\u0142owiec \u0141, Osiak J, Wo\u0142owiec A, Wijata A, Grze\u015bk E, Kozakiewicz M, et al. Inclisiran-safety and effectiveness of small interfering RNA in inhibition of PCSK-9. Pharmaceutics. 2023;15(2):323. https:\/\/doi.org\/10.3390\/pharmaceutics15020323.","journal-title":"Pharmaceutics"},{"key":"1033_CR159","unstructured":"World Health Organization. (2021). Ethics and governance of artificial intelligence for health. World Health Organization, 1\u2013165. ISBN 978-92-4-002920-0 (electronic version)"},{"issue":"1","key":"1033_CR160","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12951-022-01399-5","volume":"20","author":"YN Xia","year":"2022","unstructured":"Xia YN, Zu H, Guo H, Jiang T, Yang S, Yu H, et al. Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents. J Nanobiotechnol. 2022;20(1):185. https:\/\/doi.org\/10.1186\/s12951-022-01399-5.","journal-title":"J Nanobiotechnol"},{"issue":"10","key":"1033_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60101646","volume":"60","author":"G Xiao","year":"2024","unstructured":"Xiao G, Gao S, Xie Y, Wang Z, Shu M. Efficacy and safety of evolocumab and alirocumab as PCSK9 inhibitors in pediatric patients with familial hypercholesterolemia: a systematic review and meta-analysis. Medicina. 2024;60(10):1646. https:\/\/doi.org\/10.3390\/medicina60101646.","journal-title":"Medicina"},{"issue":"4","key":"1033_CR162","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/metabo15040248","volume":"15","author":"S Xiong","year":"2025","unstructured":"Xiong S. Gut-microbiota-driven lipid metabolism: mechanisms and applications in swine production. Metabolites. 2025;15(4):248. https:\/\/doi.org\/10.3390\/metabo15040248.","journal-title":"Metabolites"},{"issue":"2","key":"1033_CR163","doi-asserted-by":"publisher","first-page":"e00060","DOI":"10.1128\/cmr.00060-22","volume":"37","author":"A Yadegar","year":"2024","unstructured":"Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024;37(2):e00060-e122. https:\/\/doi.org\/10.1128\/cmr.00060-22.","journal-title":"Clin Microbiol Rev"},{"key":"1033_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.573475","volume":"11","author":"R Yang","year":"2020","unstructured":"Yang R, Hu X, Xie X, Chen H, Fang H, Zhu L, et al. Propionic acid targets the TLR4\/NF-\u03ba B signaling pathway and inhibits LPS-induced intestinal barrier dysfunction: in vitro and in vivo studies. Front Pharmacol. 2020;11:573475. https:\/\/doi.org\/10.3389\/fphar.2020.573475.","journal-title":"Front Pharmacol"},{"key":"1033_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1147699","volume":"10","author":"TM Yang","year":"2023","unstructured":"Yang TM, Miao M, Yu WQ, Wang X, Xia FJ, Li YJ, et al. Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: a narrow review. Front Mol Biosci. 2023;10:1147699. https:\/\/doi.org\/10.3389\/fmolb.2023.1147699.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"1033_CR166","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1161\/CIRCULATIONAHA.114.01069","volume":"131","author":"C Yao","year":"2015","unstructured":"Yao C, Chen BH, Joehanes R, Otlu B, Zhang X, Liu C, et al. Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes. Circulation. 2015;131(6):536\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.01069.","journal-title":"Circulation"},{"issue":"9","key":"1033_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25092193","volume":"25","author":"AA Yetisgin","year":"2020","unstructured":"Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. https:\/\/doi.org\/10.3390\/molecules25092193.","journal-title":"Molecules"},{"issue":"10","key":"1033_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101587","volume":"8","author":"JY Yoo","year":"2020","unstructured":"Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. https:\/\/doi.org\/10.3390\/microorganisms8101587.","journal-title":"Microorganisms"},{"issue":"12","key":"1033_CR169","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/jcm8122227","volume":"8","author":"Y Yu","year":"2019","unstructured":"Yu Y, Raka F, Adeli K. The role of the gut microbiota in lipid and lipoprotein metabolism. J Clin Med. 2019;8(12):2227. https:\/\/doi.org\/10.3390\/jcm8122227.","journal-title":"J Clin Med"},{"issue":"7","key":"1033_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/polym15071596","volume":"15","author":"A Yusuf","year":"2023","unstructured":"Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems. Polymers (Basel). 2023;15(7):1596. https:\/\/doi.org\/10.3390\/polym15071596.","journal-title":"Polymers (Basel)"},{"key":"1033_CR171","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2508286","author":"SST Zadeh","year":"2024","unstructured":"Zadeh SST, Shapiro MD. Therapeutic gene editing in dyslipidemias. Rev Cardiovasc Med. 2024. https:\/\/doi.org\/10.31083\/j.rcm2508286.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"1033_CR172","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3900835","volume":"2022","author":"T Zhai","year":"2022","unstructured":"Zhai T, Wang P, Hu X, Zheng L. Probiotics bring new hope for atherosclerosis prevention and treatment. Oxid Med Cell Longev. 2022;2022(1):3900835. https:\/\/doi.org\/10.1155\/2022\/3900835.","journal-title":"Oxid Med Cell Longev"},{"issue":"19","key":"1033_CR173","doi-asserted-by":"publisher","first-page":"e05340","DOI":"10.1002\/adhm.202505340","volume":"15","author":"H Zhang","year":"2026","unstructured":"Zhang H, Han S, Zhang X, Ma J, Jin L, Wang Y, et al. Novel lipid nanoparticle (lnp) delivery systems enabling the advancement of RNA therapeutics. Adv Healthc Mater. 2026;15(19):e05340. https:\/\/doi.org\/10.1002\/adhm.202505340.","journal-title":"Adv Healthc Mater"},{"issue":"19","key":"1033_CR174","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.3390\/foods11192961","volume":"11","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang X, Zhang X. Modulation of intestinal flora by dietary polysaccharides: a novel approach for the treatment and prevention of metabolic disorders. Foods. 2022;11(19):2961. https:\/\/doi.org\/10.3390\/foods11192961.","journal-title":"Foods"},{"issue":"1","key":"1033_CR175","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12951-024-02529-x","volume":"22","author":"J Zhen","year":"2024","unstructured":"Zhen J, Li X, Yu H, Du B. High-density lipoprotein mimetic nano-therapeutics targeting monocytes and macrophages for improved cardiovascular care: a comprehensive review. J Nanobiotechnol. 2024;22(1):263. https:\/\/doi.org\/10.1186\/s12951-024-02529-x.","journal-title":"J Nanobiotechnol"},{"key":"1033_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.106169","author":"H Zhou","year":"2025","unstructured":"Zhou H, Li F, Liu X. Early prediction of septic shock in ICU patients using machine learning: development, external validation, and explainability with SHAP. Int J Med Inform. 2025. https:\/\/doi.org\/10.1016\/j.ijmedinf.2025.106169.","journal-title":"Int J Med Inform"},{"issue":"1","key":"1033_CR177","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.livres.2025.02.001","volume":"9","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Sun L, Zhou W, Gao W, Yuan X, Zhou H, et al. Probiotic Bifidobacterium reduces serum TMAO in unstable angina patients via the gut to liver to heart axis. Liver Res. 2025;9(1):57\u201365. https:\/\/doi.org\/10.1016\/j.livres.2025.02.001.","journal-title":"Liver Res"},{"issue":"3","key":"1033_CR178","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3892\/ijmm.2020.4674","volume":"46","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Shui X, Liang Z, Huang Z, Qi Y, He Y, et al. Gut microbiota metabolites as integral mediators in cardiovascular diseases. Int J Mol Med. 2020;46(3):936\u201348. https:\/\/doi.org\/10.3892\/ijmm.2020.4674.","journal-title":"Int J Mol Med"},{"issue":"4","key":"1033_CR179","doi-asserted-by":"publisher","first-page":"499","DOI":"10.34297\/AJBSR.2024.23.003103","volume":"23","author":"B Zohuri","year":"2024","unstructured":"Zohuri B. Harnessing artificial intelligence for advancements in biomedical research. Am J Biomed Sci Res. 2024;23(4):499\u2013503. https:\/\/doi.org\/10.34297\/AJBSR.2024.23.003103.","journal-title":"Am J Biomed Sci Res"},{"key":"1033_CR180","doi-asserted-by":"publisher","unstructured":"Singh, S., & Jha, M. K. (2024). Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease. Current Bioactive Compounds, 20(1), 43-52. https:\/\/doi.org\/10.2174\/0115734072270060230921093431","DOI":"10.2174\/0115734072270060230921093431"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01033-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:59Z","timestamp":1793412179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01033-8","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. This work has not been previously presented in any form.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required for this study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this study, artificial intelligence tools were used to improve the readability and language of the text or to generate visuals. The author subsequently reviewed and edited the content generated by the AI tools as needed and is fully responsible for the final content of this study.","order":5,"name":"Ethics","label":"Use of Artificial Intelligence Tools","group":{"name":"EthicsHeading","label":"Declarations"}}]}}